Brokerages Set Immunocore Holdings plc (NASDAQ:IMCR) PT at $80.70

Shares of Immunocore Holdings plc (NASDAQ:IMCR) have been given an average rating of “Moderate Buy” by the twelve ratings firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $80.70.

A number of research firms have recently issued reports on IMCR. Oppenheimer reiterated an “outperform” rating and issued a $89.00 price objective (up from $87.00) on shares of Immunocore in a report on Friday, August 9th. JPMorgan Chase & Co. dropped their price target on shares of Immunocore from $70.00 to $66.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 10th. HC Wainwright reissued a “buy” rating and issued a $100.00 price objective on shares of Immunocore in a research report on Wednesday, August 28th. Mizuho lowered their price objective on shares of Immunocore from $90.00 to $88.00 and set a “buy” rating on the stock in a research note on Monday, May 13th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $81.00 target price on shares of Immunocore in a research note on Friday, August 9th.

Hedge Funds Weigh In On Immunocore

Several large investors have recently modified their holdings of IMCR. Jump Financial LLC raised its position in shares of Immunocore by 57.2% in the fourth quarter. Jump Financial LLC now owns 44,900 shares of the company’s stock valued at $3,068,000 after purchasing an additional 16,345 shares during the period. First Turn Management LLC bought a new position in shares of Immunocore in the fourth quarter valued at about $23,439,000. Fiera Capital Corp raised its position in shares of Immunocore by 24.6% in the fourth quarter. Fiera Capital Corp now owns 846,787 shares of the company’s stock valued at $57,852,000 after purchasing an additional 166,988 shares during the period. Robeco Institutional Asset Management B.V. bought a new position in shares of Immunocore in the fourth quarter valued at about $5,064,000. Finally, Trexquant Investment LP increased its position in Immunocore by 6.5% during the fourth quarter. Trexquant Investment LP now owns 28,545 shares of the company’s stock worth $1,950,000 after acquiring an additional 1,746 shares during the period. 84.50% of the stock is owned by institutional investors.

Immunocore Price Performance

NASDAQ IMCR opened at $33.40 on Monday. The company has a quick ratio of 5.15, a current ratio of 5.17 and a debt-to-equity ratio of 1.31. Immunocore has a 12-month low of $33.04 and a 12-month high of $76.98. The company has a market capitalization of $1.67 billion, a PE ratio of -27.38 and a beta of 0.73. The firm’s 50 day moving average is $37.57 and its 200-day moving average is $48.96.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.25. Immunocore had a negative net margin of 19.16% and a negative return on equity of 14.68%. The company had revenue of $75.40 million for the quarter, compared to the consensus estimate of $74.58 million. During the same period last year, the company earned ($0.37) earnings per share. The firm’s revenue was up 26.2% compared to the same quarter last year. Equities research analysts anticipate that Immunocore will post -1.79 earnings per share for the current fiscal year.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.